WHO says plasma therapy still ‘experimental’

By: |
August 24, 2020 6:24 PM

WHO's chief scientist Dr Soumya Swaminathan said convalescent plasma therapy has been used in the last century to treat numerous infectious diseases, with varying levels of success.

President Donald Trump on Sunday approved an emergency authorisation of convalescent plasma for COVID-19 patients.President Donald Trump on Sunday approved an emergency authorisation of convalescent plasma for COVID-19 patients.

The World Health Organisation says using plasma from the recovered to treat COVID-19 is still considered an experimental therapy and that the preliminary results showing it may work are still inconclusive.

President Donald Trump on Sunday approved an emergency authorisation of convalescent plasma for COVID-19 patients.

WHO’s chief scientist Dr Soumya Swaminathan said convalescent plasma therapy has been used in the last century to treat numerous infectious diseases, with varying levels of success. Swaminathan says WHO still considers convalescent plasma therapy to be experimental and said it should continue to be evaluated.

She added that the treatment is difficult to standardise, since people produce different levels of antibodies and the plasma must be collected individually from recovered patients.

Swaminathan says that the studies have been small and provided low-quality evidence.

She says countries can do an emergency listing if they feel the benefits outweigh the risks but that that’s “usually done when you’re waiting for the more definitive evidence.

Dr Bruce Aylward, a senior adviser to WHO’s director-general, said that convalescent plasma therapy can come with numerous side effects, from a mild fever and chills to more severe lung-related injuries.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Covid-19 vaccine update: Phase 3 human clinical trial of Oxford vaccine begins in Pune
2India needs to invest Rs 3,000-5,000 crore to create extra manufacturing facilities for COVID-19 vaccine: Zydus Cadila chairman
3Bihar combats COVID-19: Gap narrows between fresh cases, recoveries